• TENOF is indicated for the treatment of chronic hepatitis B in adults and pediatric patients 12 years of age and older • TENOF is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and pediatric patients 2 years of age and older.
Mode of Action
Tenofovir DF belongs to a class (group) of drugs called nucleoside reverse transcriptase inhibitors (NRTIs). NRTIs block an enzyme called reverse transcriptase demonstrating clinical utility against a broad spectrum of viral infections
The oral bioavailability of a 300 mg dose of TENOF is 25% in the fasted state. Administration with high fat meal increases TENOF AUC and Cmax by 40% and 14%, respectively. Protein binding in vitro is less than 7%. It is not appreciably metabolized by the liver and the renal route is the primary elimination pathway.
Dosage and Recommendation
Adults and Adolescents: 300 mg orally once daily with a meal. Children: dose has not been established.
Packing and Presentation
TENOF DF is available as HDPE container of 28 tablets.